Clinical trial · Observational
Effect of Nutritional Indices on the Prognosis of HCC Patients
Study on the Effect of Nutritional Indices on the Prognosis of Hepatocellular Carcinoma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary liver cancer has recently ranked among the leading causes of cancer death, with hepatocellular carcinoma (HCC) accounting for 75%-85% of these cases. In recent years, immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs) have achieved good results in the treatment of advanced HCC patients. So far, there is a lack of studies exploring the relationship between nutritional index and the prognosis of HCC patients treated with ICIs combined with TKIs, and there are few studies on the prognostic value of nutritional index in HCC patients treated with transarterial chemoembolization (TACE). This retrospective study aims to analyze the prognostic value of prognostic nutritional index(PNI)，body mass index (BMI), psoas muscle index（PMI）and geriatric nutritional risk index (GNRI) in HCC patients who received ICIs combined with TKIs or TACE, and to provide reference for the selection of nutritional intervention programs for HCC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- HCC patients who received ICIs combined with TKIs
- description
- HCC patients who received ICIs combined with TKIs regularly and periodically.
- label
- HCC patients treated with TACE
- description
- HCC patients who underwent TACE as initial treatment.
Primary outcomes (1)
- measure
- Death
- timeFrame
- November 2022 to May 2024
- description
- Death due to hepatocellular carcinoma progression
Secondary outcomes (1)
- measure
- Censored
- timeFrame
- November 2022 to May 2024
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Cohort 1:HCC patients received ICIs combined with TKIs regularly and periodically. Cohort 2:HCC patients who underwent TACE as initial treatment. Exclusion Criteria: 1. Patients with systemic malignant tumors other than HCC. 2. Patients with severe hypertension, diabetes, coronary heart disease, systemic infection and other serious diseases. 3. patients with immunodeficiency or autoimmune diseases. 4. Patients with severe malnutrition. 5. Not adhering to regular and periodic treatment. 6. Patients without regular follow-up or with missing data to be collected.
References
Publications (1)
- DERIVEDLuo N, Li H, Luo Y, Hu P, Liang L, Zhang R, Zhang D, Cai D, Kang J. Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors. Hum Vaccin Immunother. 2023 Aug;19(2):2258567. doi: 10.1080/21645515.2023.2258567. Epub 2023 Sep 20. PMID 37728115